Rituximab Monoclonal Antibody Injection from Japan
Rituximab is a genetically engineered chimeric monoclonal antibody targeting CD20 on B-cells, used for treating non-Hodgkin lymphoma and rheumatoid arthritis. It is supplied as an injection in measured doses for retail sale, qualifying under tariff item 3002.15.00 as an immunological product. This product directly regulates immunological processes in B-cell-mediated conditions.
Duty Rate — Japan → Canada
0%
Import Tips
• Confirm the injection is in retail packaging with measured doses
• Have the product monograph and batch records ready for CBSA
• Verify if a Drug Identification Number is required by Health Canada